| NexLife | Ro | |
|---|---|---|
| Model | Compounded tirzepatide and semaglutide, cash pay | Brand GLP-1s, membership plus medication at self-pay prices; no compounded |
| Tirzepatide price | Compounded: $129 month to month; $125, $119, $115 a month on 3-, 6-, 12-month plans | Zepbound KwikPen: $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg under Lilly's refill terms) |
| Billing basis | Per month; same price at every dose | Membership monthly or prepaid annually; medication per fill (a KwikPen fill is four weekly doses, 28 days) |
| Membership | None | $39 to start (refunded if not eligible), then $74 to $149 a month; $74 a month prepaid annually |
| Included | Medication, provider review, nutrition plan, coaching call, 24/7 support, shipping | Membership covers the program; medication billed separately |
| Pharmacy disclosure | Three named 503A pharmacies | Not recorded in our read |
| Cancellation | Takes effect after 30 days; shipped orders final | Not recorded beyond the start-fee refund |
| FDA status | Compounded: not FDA-approved | Zepbound: FDA-approved |
What is the real choice here?
It is a product choice first. Ro sells access to brand Zepbound, the FDA-approved tirzepatide product, at Lilly's self-pay prices plus a membership. NexLife sells compounded tirzepatide, made with the drug in Zepbound but not the same product and not FDA-approved, at one all-in price. Our Zepbound page covers the label: weekly injections starting at 2.5 mg, stepping up by 2.5 mg every four weeks as directed by your prescriber.
A first-year bill: Zepbound through Ro vs compounded tirzepatide
This scenario follows the label's starting steps for Zepbound and assumes Ro's prepaid annual membership. Lilly's savings terms, read October 15, 2026, allow 11 fills in a calendar year, and each fill covers 28 days. That caps a year of Zepbound at 308 days of medication.
| Cost line | Ro with Zepbound KwikPen | NexLife, 12-month plan |
|---|---|---|
| Medication | $299 (2.5 mg) + $399 (5 mg) + 9 × $449 = $4,739 for 11 fills | 12 × $115 = $1,380 (included) |
| Membership | 12 × $74 = $888 (prepaid annual) | $0 |
| Total | $5,627 | $1,380 |
| Days of medication | 308 | 12 months |
Three caveats. Ro's $449 price at 7.5 mg and above depends on each refill being bought within 45 days, per Lilly's terms; miss that and the price rises to $499 at 7.5 mg or $699 at 10 to 15 mg. Lilly's terms say the savings end December 31, 2026, so fills in 2027 may cost something different. And Ro's page did not say whether the $39 start fee is added to a prepaid annual plan.
Why don't the months line up?
Because brand pens are sold in 28-day fills and NexLife prices by the month. Thirteen 28-day periods make a year, but Lilly's savings terms stop at 11 fills per calendar year, so Ro's column covers 308 days, not 365. NexLife's 12-month plan covers 12 months of shipments. If anything, the gap in the table understates the difference in coverage.
Does the picture change for semaglutide?
Not much. Ro listed the Wegovy pen at $199 for the first two fills (0.25 and 0.5 mg) and $349 from 1 mg to 2.4 mg. As arithmetic, two fills at $199 and eleven at $349 cover 52 weeks for $4,237, plus $888 in prepaid membership: $5,125. NexLife's 12-month compounded semaglutide plan is $1,140 as of November 6, 2026. Ro also listed the Wegovy pill ($149 to $299 by dose), an option with no compounded equivalent at NexLife.
What neither page told us
- Ro: which membership tier costs what, the dispensing pharmacy, and full cancellation terms; ro.co returned HTTP 403 on October 15 and November 8, 2026.
- NexLife: whether a 12-month plan is charged upfront (its FAQ) or month by month (its cancellation policy), and which of its pharmacies fills a given order.
- Both: whether lab work is required before prescribing and who pays for it.
Where Ro has the edge
- An FDA-approved product. Zepbound's manufacturing and labeling are FDA-reviewed; compounded tirzepatide's are not.
- Medicare Bridge eligibility. If you are on Medicare Part D, the Bridge sets a $50 copay for eligible enrollees on the Zepbound KwikPen, Wegovy or Foundayo from July 1, 2026 to December 31, 2027. Compounded drugs are not covered. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge.
- Sleep apnea. Zepbound's label includes moderate-to-severe obstructive sleep apnea in adults with obesity; a compounded product carries no such indication.
Where NexLife has the edge
- Cost. $1,380 for a 12-month plan against $5,627 in our Ro scenario.
- One bill. No membership, and the same price at every dose, so moving from 2.5 mg to 15 mg does not change what you pay.
- Disclosure. Named pharmacies and printed cancellation terms, neither of which we found on Ro's pricing page.
Bottom line
If you want brand Zepbound, or Medicare or insurance would pay for it, Ro is the more fitting route of the two, and its per-dose prices are easy to check against Lilly's. If you are paying cash and are comfortable with compounded medication, NexLife costs roughly a quarter as much on these printed prices. NexLife is our editorial pick, an editorial selection. See the full Ro review, the NexLife review and our Medicare Part D guide.
Frequently asked questions
Is NexLife's tirzepatide the same as Zepbound from Ro?
No. Ro prescribes Zepbound, the FDA-approved brand made by Lilly. NexLife prescribes compounded tirzepatide, made with the drug in Zepbound by state-licensed 503A pharmacies, but not the same product and not FDA-approved. FDA does not review compounded drugs for safety, effectiveness or quality before they are sold.
How much does a year of Zepbound through Ro cost?
As arithmetic from Ro's September 17, 2026 prices, a first year of 11 KwikPen fills (one at 2.5 mg, one at 5 mg, nine at 7.5 mg or higher) comes to $4,739, plus $888 for the prepaid annual membership, or $5,627. Lilly's terms allow 11 fills a calendar year, so that covers 308 days. Missing the 45-day refill window raises the price.
How much is NexLife's compounded tirzepatide for a year?
As of November 6, 2026, NexLife's 12-month tirzepatide plan is $115 a month, or $1,380 for the year, with no membership and the same price at every dose. Month to month it is $129, or $1,548 over 12 months as arithmetic. The price includes provider review, a nutrition plan, a coaching call, support and shipping.
Can Medicare pay for Zepbound but not NexLife?
Under the Medicare GLP-1 Bridge, eligible Part D enrollees pay a $50 copay for Foundayo, Wegovy or the Zepbound KwikPen from July 1, 2026 to December 31, 2027. The Bridge does not cover vials or compounded drugs, so NexLife would be cash pay. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge.
Does Ro offer compounded tirzepatide?
Not in our September 17, 2026 read. Ro's pricing page listed only FDA-approved brand drugs: the Wegovy pill, the Wegovy pen and the Zepbound KwikPen, billed separately from the membership. Ro blocked our October and November re-reads, so check ro.co for any change.
Sources
- NexLife: tirzepatide plans — prices as of 2026-11-06; pharmacies and cancellation wording read 2026-10-15
- Ro: weight loss pricing — read 2026-09-17; re-reads returned HTTP 403 on 2026-10-15 and 2026-11-08
- Lilly: LillyDirect Zepbound self-pay terms — prices, 45-day refill rule and 11-fill limit read 2026-10-15
- FDA label (DailyMed): Zepbound prescribing information — label revised 08/2026; read 2026-11-08
- Medicare.gov: Weight-loss drug coverage (GLP-1 Bridge) — $50 copay, covered drugs and exclusions read 2026-11-08
Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.
Check NexLife's plans and state availability → See the price index